Latest Alzheimer's news and updates from Switzerland. AI-curated articles covering Alzheimer's topics.
Swiss medicines regulator Swissmedic has approved Kisunla (donanemab) for early-stage Alzheimer's but not Leqembi (lecanemab), a drug already available in over 50 countries. The decision leaves Swiss patients with fewer advanced treatment options compared to many other nations.
In a landmark decision, Swissmedic has authorized Donanemab, the first drug proven to slow the cognitive decline associated with Alzheimer's disease. The approval offers new hope for patients in the early stages of the illness, though questions surrounding health insurance coverage remain.
In a landmark decision, Swiss medicines regulator Swissmedic has authorised Donanemab, the first drug in Switzerland that can slow the cognitive decline associated with early-stage Alzheimer's disease.
Swissmedic, the national regulator, has approved Donanemab (Kisunla), the first drug in Switzerland that can slow the progression of Alzheimer's disease in patients at an early stage. While patient groups welcome the news, questions remain about whether health insurance will cover the costs of the treatment.
From trusted Swiss news outlets